Werewolf Therapeutics (NASDAQ:HOWL) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Stock Up 102.6%

NASDAQ:HOWL opened at $0.87 on Friday. The stock’s 50 day moving average price is $0.39 and its two-hundred day moving average price is $0.58. The firm has a market capitalization of $42.45 million, a price-to-earnings ratio of -1.15 and a beta of 0.29. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to analyst estimates of $21.00 million. Equities research analysts expect that Werewolf Therapeutics will post -1.08 EPS for the current year.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the sale, the insider directly owned 303,719 shares in the company, valued at $106,301.65. This represents a 57.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,218,524 shares of company stock worth $851,252 over the last ninety days. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at $112,000. BlackRock Inc. acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $37,000. Regal Investment Advisors LLC grew its holdings in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics News Roundup

Here are the key news stories impacting Werewolf Therapeutics this week:

• Positive Sentiment: The proposed merger would bring a Phase 3 asset into the combined company. Neridronate is being evaluated in the ongoing CRPS-RISE trial and could become the first FDA-approved drug specifically for CRPS-1, a debilitating condition affecting approximately 65,000 newly diagnosed U.S. patients annually. The drug has received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. Werewolf and Ambros Therapeutics announce merger
• Positive Sentiment: The oversubscribed $150 million financing, backed by healthcare investors including RA Capital Management and Janus Henderson Investors, is expected to fund operations through CRPS-RISE topline results anticipated in 2028 and a potential FDA filing, with cash runway projected into the first half of 2029. Merger agreement and private placement
• Neutral Sentiment: The transaction is expected to close by the first quarter of 2027, subject to shareholder approvals, SEC registration and other customary conditions. After closing, the company is expected to operate as Ambros Therapeutics and trade under the ticker AMBX. Werewolf Therapeutics to merge with Ambros Therapeutics
• Negative Sentiment: The deal substantially dilutes existing HOWL holders: pre-merger Werewolf stockholders are expected to own approximately 6.8% of the combined company, while Ambros shareholders would own about 71.7% and financing investors 21.5%. The implied transaction value for Werewolf is $47.5 million versus $500 million for Ambros.
• Negative Sentiment: Investors still face clinical, regulatory and closing risks. Neridronate must produce positive Phase 3 results, and the FDA could require additional data or trials; the financing and merger could also be delayed or fail to close.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.